Individualised variable-interval risk-based screening for sight-threatening diabetic retinopathy: the Liverpool Risk Calculation Engine by Eleuteri, Antonio et al.
Article
Individualised variable-interval risk-based 
screening for sight-threatening diabetic 
retinopathy: the Liverpool Risk Calculation 
Engine
Eleuteri, Antonio, Fisher, Anthony C., Broadbent, Deborah M., 
García-Fiñana, Marta, Cheyne, Christopher P., Wang, Amu, Stratton, 
Irene M., Gabbay, Mark, Seddon, Daniel, Harding, Simon P. and 
Thetford, Clare
Available at http://clok.uclan.ac.uk/35920/
Eleuteri, Antonio, Fisher, Anthony C., Broadbent, Deborah M., García-Fiñana, Marta, 
Cheyne, Christopher P., Wang, Amu, Stratton, Irene M., Gabbay, Mark, Seddon, Daniel 
et al (2017) Individualised variable-interval risk-based screening for sight-threatening 
diabetic retinopathy: the Liverpool Risk Calculation Engine. Diabetologia, 60 (11). pp. 
2174-2182. ISSN 0012-186X  
It is advisable to refer to the publisher’s version if you intend to cite from the work.
http://dx.doi.org/10.1007/s00125-017-4386-0
For more information about UCLan’s research in this area go to 
http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.
For information about Research generally at UCLan please go to 
http://www.uclan.ac.uk/research/ 
All outputs in CLoK are protected by Intellectual Property Rights law, including
Copyright law.  Copyright, IPR and Moral Rights for the works on this site are retained 
by the individual authors and/or other copyright owners. Terms and conditions for use 
of this material are defined in the http://clok.uclan.ac.uk/policies/
CLoK
Central Lancashire online Knowledge
www.clok.uclan.ac.uk
ARTICLE
Individualised variable-interval risk-based screening
for sight-threatening diabetic retinopathy: the Liverpool Risk
Calculation Engine
Antonio Eleuteri1 & Anthony C. Fisher1 & Deborah M. Broadbent2,3 &
Marta García-Fiñana4 & Christopher P. Cheyne4 & Amu Wang2 & Irene M. Stratton5 &
MarkGabbay6 & Daniel Seddon7 & Simon P. Harding2,3 & for the Individualised Screening
for Diabetic Retinopathy (ISDR) Study Group
Received: 21 January 2017 /Accepted: 12 June 2017 /Published online: 24 August 2017
# The Author(s) 2017. This article is an open access publication
Abstract
Aims/hypothesis Individualised variable-interval risk-based
screening offers better targeting and improved cost-
effectiveness in screening for diabetic retinopathy. We devel-
oped a generalisable risk calculation engine (RCE) to assign
personalised intervals linked to local population characteris-
tics, and explored differences in assignment compared with
current practice.
Methods Data from 5 years of photographic screening and
primary care for people with diabetes, screen negative at the
first of > 1 episode, were combined in a purpose-built near-
real-time warehouse. Covariates were selected from a dataset
created using mixed qualitative/quantitative methods. Markov
modelling predicted progression to screen-positive (referable
diabetic retinopathy) against the local cohort history.
Retinopathy grade informed baseline risk and multiple impu-
tation dealt with missing data. Acceptable intervals (6, 12,
24 months) and risk threshold (2.5%) were established with
patients and professional end users.
Results Data were from 11,806 people with diabetes (46,525
episodes, 388 screen-positive). Covariates with sufficient
predictive value were: duration of known disease, HbA1c,
age, systolic BP and total cholesterol. Corrected AUC
(95% CIs) were: 6 months 0.88 (0.83, 0.93), 12 months
0.90 (0.87, 0.93) and 24 months 0.91 (0.87, 0.94).
Sensitivities/specificities for a 2.5% risk were: 6 months
0.61, 0.93, 12 months 0.67, 0.90 and 24 months 0.82,
0.81. Implementing individualised RCE-based intervals
would reduce the proportion of people becoming screen-
positive before the allocated screening date by > 50% and
the number of episodes by 30%.
Conclusions/interpretation The Liverpool RCE shows suffi-
cient performance for a local introduction into practice before
wider implementation, subject to external validation. This ap-
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proach offers potential enhancements of screening in im-
proved local applicability, targeting and cost-effectiveness.
Keywords Diabetic retinopathy . Risk calculation engine .
Risk-based screening
Abbreviations
AICc Corrected Akaike’s information criterion
LDESP Liverpool Diabetes Eye Screening Programme
RCE Risk calculation engine
STDR Sight-threatening diabetic retinopathy
Introduction
Systematic screening for sight-threatening diabetic retinopathy
(STDR) has been introduced in several European countries and
regionally throughout the world, and has been a major driver of
improved detection and early treatment. As a doubling of the
global prevalence of diabetes mellitus is expected by 2030 [1],
with over 10% having STDR [2], there is an urgent need to
improve the cost-effectiveness of screening. While current rec-
ommendations are for annual screening intervals in most loca-
tions [3], there has been a recent move to recommend biennial
screening for people with no retinopathy [4–7], including in one
systematic review [8], and this was recently endorsed by the UK
National Screening Committee [9]. Screening at 3-yearly inter-
vals has been introduced in Sweden, based on data from one
programme [10], and is supported as being cost-effective in a
recent UK modelling study [11]. However, concerns about the
safety and acceptability of extended intervals have held back
adoption [12, 13].
Risk engines have been developed in recent years, including
in diabetes mellitus for risk of CHD [14], and one has been
proposed for diabetic retinopathy [15]. For widespread uptake,
reliable flows of data need to be established and designs need to
be applicable across a range of populations and health settings.
As part of a programme of research to improve the
targeting and cost-effectiveness of screening, we developed
a generalisable personalised screening method to allow vari-
able intervals for people with diabetes at high and low risk of
developing STDR. We developed and internally validated a
risk calculation engine (RCE) to estimate risk of progression
to screen-positive or referable diabetic retinopathy and assign
individualised screening intervals. We calculated improve-
ment in allocation of screening interval to estimate the effect
on number of screen episodes.
Methods
Dataset Data from established digital photographic screening
(OptoMize, EMIS Group, Leeds, UK) and primary care
systems (EMISweb, EMIS Group) were combined in a
purpose-built data warehouse. The local ethics committee ap-
proved an opt-out approach to consent (13/NW/0196) and the
research was conducted in accordance with the Declaration of
Helsinki 2008. Data were collected for all people recorded in
primary care as having diabetes mellitus attending the
Liverpool Diabetes Eye Screening Programme (LDESP) from
the systems used for routine service, anonymised and com-
piled before transmission to the warehouse.
A set of candidate covariates was selected for the model
using patient expert panels and a literature review of known
risk factors (see electronic supplementary material [ESM]
Methods and ESM Table 1). An RCE development dataset
was extracted from the data warehouse containing covariates
with ≥ 80% completeness in people with diabetes who were
screen negative (non-referable retinopathy) at the first of at
least two episodes that occurred in a 5 year sample period.
Disease duration was defined as duration of known diabetes
mellitus (first recorded date of diabetes or measure of HbA1c
in primary care [11]) and assigned at the first screening epi-
sode. Values of clinical risk factors prior and nearest to the
screen episode date were used.
Screen-positive (the primary outcome) was defined as the
presence of any of: multiple blot haemorrhages, venous bead-
ing, intra-retinal microvascular abnormalities, new vessels,
pre-retinal/vitreous haemorrhage, tractional retinal detach-
ment, exudates within 1 disc diameter (1500 μm) of the foveal
centre, group of exudates within the macula or blot
haemorrhages within 1 disc diameter of the foveal centre with
vision worse than 6/12.
Model description We selected a continuous-time Markov
process to allow for a set of individuals to move independent-
ly, or transition, between states over time [16]. The patient
state at each time point was defined by level of retinopathy,
including separation by one or both eye involvement after
Stratton et al [17] (Fig. 1:) (1) no diabetic retinopathy detected;
(2) non-referable diabetic retinopathy in one eye only; (3)
non-referable diabetic retinopathy in both eyes; and (4) refer-
able diabetic retinopathy (screen-positive for at least one eye).
Only one baseline screening event was used.
The risks, or intensities, for each transition were entered
into the model within a probability matrix containing
Weibull transition intensities estimated from the data
[18–20]. A detailed description is provided in the ESM
Methods.
The data in the RCE development dataset is an example of
panel data [16, 18] where information on an individual’s dis-
ease is sampled at time points not typically coincident with the
change in disease state. This interval-censoring problem is
illustrated in ESM Fig. 1 and required special methods.
Missing clinical data were handled using multiple imputation
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[21] (ESM Methods) repeated ten times to properly account
for variability due to unknown values.
Model fitting and covariate selectionCovariates meeting the
above criteria were ranked using Wald statistics. A set of
nested models were built to estimate corrected Akaike’s infor-
mation criterion (AICc). This method combines estimation
(i.e. maximum likelihood) andmodel selection under a unified
framework [16, 22, 23]. AIC was corrected to adjust for the
number of covariates (see ESM Methods); this is a method
which aims to reduce the effect of overfitting by applying a
penalty for model complexity. The model with the smallest
AICc was chosen to give the best fit to the data.
Patient expert group A patient involvement group was de-
veloped through local and national patient groups and local
advertisements with a mix of backgrounds, sex and diabetes
type. The group developed their knowledge of disease and
patient pathways and the assessment of risk over several tai-
lored sessions. At the end of these, they expressed that they
had sufficient knowledge to give considered input into the
study design. Acceptability and feasibility were considered
for the application of the RCE output for a range of risk
thresholds and alternative screen intervals.
Data validation and model checkingWe checked the devel-
opment dataset using random samples of event vectors which
were independently checked manually and programmatically.
The model was checked for influence of outliers, regression
and distributional assumptions, and Pearson-type goodness-
of-fit and corrected C-index were calculated.
Bootstrapping (to estimate the optimism of validation mea-
sures) and fourfold cross-validation were used for internal
validation (see ESM Methods). Further internal validation
was conducted using a geographical split based on the depri-
vation index [24], to assess whether the performances of the
model were unduly affected by extremes of prevalence rates
of positive screening events. Areas under the receiver operat-
ing curves were calculated as overall indicators of sensitivities
and specificities.
Implementation The effect of a set of risk thresholds (5%,
2.5%, 1%) on screening-interval allocation was investigated
using the fourfold validation sets described above, and a final
threshold selected in discussion with the patient expert group.
The proportion of screen-positive events that occurred before
the allocated interval was calculated for each risk threshold.
Overall numbers of screening episodes were calculated over a
2 year period and compared with an annual programme.
Predictions in a clinical environment (using the fittedmodel)
for new observations with missing covariates were obtained by
a simple imputation strategy: we replaced the missing values of
each covariate with a 75th percentile value estimated from full
data at first screening to give a ‘worst case’ prediction.
A small sample of cases assigned by the RCE to 6, 12 and
24 months rescreen interval were independently checked
against patient records for clinical credibility.
Results
The data repository contained 2.48 × 1010 data fields across 302
covariates. Data extracted into the RCE development dataset
were from 11,806 people with diabetes actively attending the
LDESP between 20 Feb 2009 and 4 Feb 2014 (46,525 episodes,
388 screen-positive events). Data flow is shown in ESM Fig. 2.
Covariates that met the entry criteria are listed in Table 1.
Those that gave the best fit (total rescaled AICc = 0) and were
included in the final model were: disease duration, HbA1c, age
at diagnosis, systolic BP and total cholesterol. Although the
retinopathy stage is not technically a covariate, it is included in
the table to show the improvement in predictive power when
covariates are added to the model.
The risk model is summarised in the following three equa-
tions. The first expression gives the hazard rates (or intensities,
or ‘risks’) of going from one state to another, for each of the
six transitions shown in Fig. 1, each one dependent on the full
set of covariates and the full local population history:
logλij ¼ β0ij þ βAgeDij AgeDþ βDiseaseDij DiseaseDþ⋯
þ βSPij SBP ð1Þ
where i , j = {1, 2, 3, 4} and βCij is the model parameter for
covariate C (or baseline intensity when C = 0); AgeD is age
at diagnosis, DiseaseD is disease duration.
No DR
(1)
Non-referable DR
(two eyes)
(3)
Non-referable DR
(one eye)
(2)
Referable DR
(at least one eye)
(4)
Fig. 1 Transitions between
diabetic retinopathy disease states
of the continuous-time Markov
process in the Liverpool RCE.
DR, diabetic retinopathy
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From the hazard rates function (1), a transition intensity
matrix is derived for the four states (each row sums to 0):
Q ¼
−λ11 λ12 0 0
λ21 −λ21−λ23−λ24 λ23 λ24
0 λ32 −λ32−λ34 λ34
0 0 0 0
0
BB@
1
CCA ð2Þ
ESM Fig. 3 shows the two baseline transition intensities to
the screen-positive state in the rightmost column of Eq. (2).
Probabilities of transition occurring at a specific time t are
obtained by using the following equation:
P tð Þ ¼ exp Qt0:9  ð3Þ
where the exp() operator is the matrix exponential and α = 0.9
is the estimated Weibull shape parameter. The shape parame-
ter 0.9 reflects the clinical observation that a person is more
likely to move between disease states earlier rather than later.
Table 2 shows the estimated baseline hazard ratios, with
95% CIs. In Table 3, we report the estimated baseline proba-
bilities of each state transition, with 95% CIs.
Further details are given in ESM Methods.
Data and model checking The pseudo-likelihood ratio p val-
ue for the summary residuals vs time was 0.04, suggesting
linearity to hold between 0 and 2 years, with a possible lack
of fit beyond 2 years (ESM Fig. 4). Although the p value was
below 0.05, there is not enough evidence of a lack of fit be-
cause of the small number of events relative to the model
complexity [20, 22]. Cox–Snell residuals are shown in ESM
Fig. 5: the calibration curve was close to the theoretical opti-
mal calibration, showing that the model tended to give slightly
pessimistic predictions of failure. The Pearson-type statistic
for the Liverpool RCE model was 0.57, denoting not enough
evidence to reject the null hypothesis of good fit. Cross-
Table 1 Ten covariates included
in the initial model with corre-
sponding Wald statistics, rescaled
corrected AICc and proportions
of explained likelihood
Covariate Wald statistic Rescaled AICc % Explained likelihood
Retinopathy (baseline)a 893.65 –
+ Disease duration (years)a 293.4 423.23 48
+ HbA1c (mmol/mol)
a 201.2 68.61 85
+ Age at diagnosis (years)a 44.2 10.85 92
+ Systolic BP (mmHg)a 18.9 6.61 94
+ Total cholesterol (mmol/l)a 18.7 0 96
+ Disease type 15.2 0.99 97.5
+ Diastolic BP (mmHg) 8.2 5.61 98.6
+ eGFR (ml min−1 1.73 m−2) 5.4 13.63 99.4
+ Sex 5.1 24.95 99.9
+ HDL-cholesterol (mmol/l) 0.73 40.99 –
a Covariates included in the final model
Table 2 Baseline hazard ratios for each transition
Transition AgeD DiseaseD HbA1c Chol SBP
1 → 2 1.00450 (1.00115, 1.00787) 1.0280 (1.0213, 1.0348) 1.0101 (1.00743, 1.0128) 0.963 (0.923, 1.00521) 1.00409 (1.00104, 0.0073)
2 → 1 1.00580 (1.00237, 1.00919) 0.983 (0.975, 0.992) 0.998 (0.995, 1.00140) 1.0153 (0.973, 1.0592) 0.999 (0.996, 1.00244)
2 → 3 0.989 (0.984, 0.994) 1.0261 (1.0173, 1.0350) 1.00621 (1.00221, 1.0102) 0.965 (0.901, 1.0333) 0.998 (0.993, 1.00255)
2 → 4 1.0245 (0.990, 1.0605) 0.989 (0.931, 1.0510) 1.00554 (0.983, 1.0285) 1.0231 (−0.27, 0.37) 1.00342 (0.977, 1.0310)
3 → 2 1.00839 (1.00329, 1.0135) 0.959 (0.949, 0.968) 0.990 (0.985, 0.994) 1.0836 (1.0147, 1.157) 0.997 (0.993, 1.00126)
3 → 4 0.986 (0.977, 0.995) 1.00420 (0.989, 1.0200) 1.0164 (1.00888, 1.0239) 1.0346 (0.918, 1.166) 1.00501 (0.996, 1.0141)
95% CIs shown
AgeD, age at diagnosis
Chol, cholesterol
DiseaseD, disease duration
SBP, systolic BP
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validation showed only very small effects, i.e. the training and
test performance measures were essentially the same. Fitting
the model to the most deprived 65% of individuals produced
only very small changes in risk allocation of the non-deprived
group.
The patient expert panel identified acceptable screen inter-
vals of 6, 12 and 24 months and risks of 1% and 2.5% as
acceptable risks of missing screen-positive disease at any future
screen episode. Exploration of the effect of different risk thresh-
olds on allocation to the three different screen intervals using
our four-way cross-validation is shown in Table 4. As the risk
threshold decreased, the proportion of incorrect screen-interval
allocations decreased for screen positives (overestimation) and
increased (underestimation) for screen negatives.
For an annual interval, the overestimation was 50.2% and
underestimation 100%; when compared with this interval, the
number of individuals correctly allocated was greater for the
model with any of the three thresholds. The number of inter-
vals which were either over- or underestimated was also lower
for the model at all three thresholds. Table 5 shows the de-
tailed comparison between the overall numbers of screening
episodes in an annual programme and the Liverpool RCE
model. For all three risk thresholds, there was a reduction in
the overall number of screening episodes required
(summarised in Table 4). The research team and patient expert
panel considered that a 2.5% criterion showed a satisfactory
distribution across the three screening intervals and a reason-
able reduction in episodes, and this was selected for
implementation.
Using the 2.5% threshold, the corrected C-index for the
model was 0.687 and corrected AUCs (with 95% CIs) were
0.88 (0.83, 0.93) at 6 months, 0.90 (0.87, 0.93) at 12 months
Table 3 Baseline prob-
abilities of state transi-
tion at 1 year
Transition Probability
1 → 2 0.114 (0.111, 0.118)
2 → 1 0.552 (0.541, 0.565)
2 → 3 0.141 (0.134, 0.148)
2 → 4 0.0163 (0.0139, 0.0202)
3 → 2 0.283 (0.272, 0.294)
3 → 4 0.0574 (0.0485, 0.0678)
95% CIs shown
Table 4 Analysis of the effect of allocation of screening interval by the RCE compared with annual interval
Screening
Variable Individualised based on the Liverpool RCE Annual
Risk threshold
5% 2.5% 1%
Screening intervala
6 months 5.5% 10.7% 26.3% 0%
12 months 4.4% 8.6% 9.3% 100%
24 months 90.1% 80.7% 64.4% 0%
Screen-positive (%)b
Correct allocation: events occurring after the predicted
screening date
65.6% 78.0% 91.1% 49.8%
Incorrect allocation: events occurring before the
predicted screening date (overestimated)
34.4% 22.0% 8.9% 50.2%
Screen negative (%)b
Correct allocationc 90.4% 79.8% 62.2% 0%
Incorrect allocation: screening date given ‘too early’
(underestimated)
9.6% 20.2% 37.8% 100%
Proportion of reduction in visits compared with annual interval 39.5% 29.7% 5.9% Reference value
a Proportion of individuals allocated to 6, 12 and 24 month screening using 5%, 2.5% and 1% risk thresholds
b Distribution of screen-positive and -negative events depending on risk threshold is also shown, followed by the proportion of reduction of visits
compared with annual screening
c Excluded data from individuals with insufficient follow-up data
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and 0.91 (0.87, 0.94) at 24 months. The four-way random data
split gave sensitivities and specificities for a risk threshold of
2.5% at 6, 12 and 24 months, respectively: 6 months 0.61,
0.93; 12 months 0.67, 0.90; and 24 months 0.82, 0.81.
Clinical review of sampled cases (n = 18) indicated that
allocations to individualised screen intervals appeared
reasonable.
Discussion
We have developed and tested an RCE in which an individ-
ual’s risk can be predicted from contemporaneous routinely
collected clinical data, referenced to the clinical histories of
the local population, using covariates of local relevance. The
risk can be reassessed at each screening episode as new clin-
ical information is acquired.
The Markov approach we have used allows a dynamic
model of the retinopathy history to be built. In a sense,
the model ‘compresses’ the information about time evolu-
tion. The Markov property can be summarised by the
phrase ‘The future is predicted from the past through the
present’, and is particularly appropriate to our setting.
The strengths of our model include our approach to tackling
the data in routine screening. Retinopathy data in screening is
interval censored [16] in that the event seems as if it has hap-
pened when it is detected. This may lead to biased estimates, as it
‘seems’ like the disease developed later than it actually did.
Unlike other ‘classic’ model types, including the Cox model,
the Markov approach can internally handle this interval censor-
ing. In addition, it predicts the probabilities of transition for all
disease states. ‘Real life’ data from routine clinical practice inev-
itably introduces missingness and recording errors. We embed-
ded amodel for multiple imputation ofmissing covariates, which
was required to allow our RCE to run effectively.
Potential limitations of our RCE relate to model design and
some of the covariates. We did not adjust for misclassification
of retinopathy during grading. This could be addressed by
Table 5 Screening episodes re-
quired over a 2 year period from
each validation set (and com-
bined) according to threshold, and
comparison with annual
screening
Specification/
model allocation
Number of screening episodes required in a 2 year period Difference from standard
allocation (%)
6
monthsa
12
monthsa
24
monthsa
Total Standard
allocationb
5%
VS1 728 238 2699 3665 6000 −2335 (−38.9)
VS2 668 262 2702 3632 6000 −2368 (−39.5)
VS3 712 274 2685 3671 6000 −2329 (−38.8)
VS4 548 288 2719 3555 6000 −2445 (−40.8)
Overall 2656 1062 10,805 14,523 24,000 −9477 (−39.5)
2.5%
VS1 1276 460 2451 4187 6000 −1813 (−30.2)
VS2 1280 526 2417 4223 6000 −1777 (−29.6)
VS3 1308 544 2401 4253 6000 −1747 (−29.1)
VS4 1260 540 2415 4215 6000 −1785 (−29.8)
Overall 5124 2070 9684 16,878 24,000 −7122 (−29.7)
1%
VS1 3140 546 1942 5628 6000 −372 (−6.2)
VS2 3124 584 1927 5635 6000 −365 (−6.1)
VS3 3208 548 1924 5680 6000 −320 (−5.3)
VS4 3136 560 1936 5632 6000 −368 (−6.1)
Overall 12,608 2238 7729 22,575 24,000 −1425 (−5.9)
Breakdown of numbers of screening episodes required over a 2 year period from each validation set (and
combined) if the cut-off was 5%, 2.5% or 1% and the midpoint of positive-screen event interval was truly
representative of when that positive event actually occurred, along with a comparison with the currently used
standard annual screening allocation
a Number of screening episodes at 6, 12 and 24 months is calculated as 4×, 2× and 1× the number of people
allocated to those screening episodes, respectively, to represent the number of screenings they would attend over a
2 year period
b Standard number of screening episodes based on all individuals given annual screening (i.e. 2× number of
individuals)
VS, validation set
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adding a misclassification model, but at the cost of substan-
tially more observations and computational complexity. Some
covariates were not informative in the Liverpool setting.
Ethnic diversity is low and the prevalence of abnormal
eGFRs <60 ml min−1 1.73 m−2 was only 14.5%. Other covar-
iates such as social deprivation score may be worth adding.
‘Type of diabetes’ may not be accurately recorded in primary
care and the increased use of insulin in type 2 diabetes makes
‘insulin usage’ an unreliable criterion. We used date of first
HbA1c test to improve data on ‘duration of diabetes’, helpful
especially in people with long durations, but less reliable since
the introduction of HbA1c as a primary screening test.
The model consistently showed good levels of prediction
for the 2.5% risk threshold. The numbers of screen-positive
cases with overestimated screening dates and screen-negative
cases with underestimated screening dates were reduced. The
majority of people were correctly allocated (78% of screen
positives, 80% of screen negatives), with a reasonable alloca-
tion of (approximately) 10%:10%:80% across the 6, 12 and
24 month intervals. The number of patients who had the
screen event before the allocated screening date was reduced
by more than half and the overall number of screening epi-
sodes was reduced by 30%.
We included a strongly embedded local patient group,
which allowed us to develop an appropriate preliminary co-
variate list and acceptable screen intervals and risk threshold.
This group developed expertise over a series of meetings and
provided substantial input into design and implementation.
Strong patient and professional involvement is very valuable
in study design and delivery.
Our RCE development process is suitable for a wide range
of geographical locations and populations with a minimum
prerequisite of a centrally maintained disease register with
adequate historical data. Revision/addition of covariates can
be accommodated based on the strength they add to a locally
developed model. For example, higher prevalence of poor
diabetes control or renal disease may strengthen the effect of
HbA1c or eGFR. Alternative intervals including extension be-
yond 24 months could be developed subject to acceptability.
Local populations may select alternative risk thresholds de-
pending on the perception of risk. We give the key steps to
developing and building such a system in the text box.
RCE development dataset
Local stakeholder engagement:
• Approvals and systems for regular data transfers
    •  Patient and professional groups for covariate           
       selection
First iteration RCE development dataset
Review processing protocols and limit criteria for local 
relevance
Data exploration and verification
Lock risk engine development dataset
Multiple imputation
(model fitting)
Covariate selection
Select preliminary Markov model using all covariates 
Assign informedness to covariates
Review with local patient and professional groups
Finalise covariates and fix model structure
RCE model
Build test model
Agree choice of screen intervals
Run diagnostics and validation
Final model version (revise if required)
RCE model
Secure domain for implementation model
Determine frequency of updating data (recommend 2 
monthly)
Re-tune model (recommend 3 yearly)
Key steps to developing a locally relevant risk 
calculation engine
2180 Diabetologia (2017) 60:2174–2182
The use of near-real-time data and a model developed from
local data in our approach is novel. Aspelund et al developed a
risk-estimatingmodel in Iceland [15]. They used a proportional
hazards Weibull model informed by local retinopathy data be-
tween 1994 and 1997 and risks for covariates estimated from
data published in the 1990s. ROC analysis showed a fair per-
formance, with 59% fewer visits than annual screening. Van
der Heijden et al tested this model in an up-to-date prospective
cohort of people with type 2 diabetes [25]. Of a total of 8303,
3319 met the eligibility criteria, with a mean of 53 months
follow-up. Discriminatory ability was good (C-statistic 0.83),
but 67 of 76 people (88.2%) who developed STDR developed
it after the time predicted by the model. This overestimation of
risk highlights the weakness of using historical data.
Hippisley-Cox and Coupland recently developed equations
to predict 10 year rates of amputation and blindness using
similar methods to us [26]. They studied routinely collected
general practice and hospital episode data from 454,575 peo-
ple with diabetes. Aweb-based 10 year calculator using Cox’s
proportional hazards models was developed. They reported
comparable C-statistics (≥ 0.73) and conducted external vali-
dation using 357 practices that used a different database. The
principal limitation of this large study was the lack of valida-
tion of the diagnosis of blindness.
Risk engines have been developed in other diseases includ-
ing coronary heart disease, stroke and lipid therapy. The UK
Prospective Diabetes Study developed a risk engine for
predicting coronary heart disease [14], now in its second ver-
sion (UKPDS Outcomes Model 2).
We included clinical risk factors in our model. It has recent-
ly been suggested that retinopathy data are sufficient to devel-
op a risk stratification to extend screening intervals for people
at low risk [27]. This may prove to be a reasonable and prag-
matic approach. We had to overcome significant challenges in
developing a near-real-time data flow; this may be too difficult
in some populations. However, we determined that including
clinical data would aid acceptance amongst the professional
community, offer better prospects for generalisability and al-
low inclusion of more frequent screening for high-risk indi-
viduals. Our view is supported by our own data [28] and those
of others [29], and also by our patient expert group. We do
recognise that, as yet, estimates of resource requirements for
the effective introduction of our type of RCE are not available.
External validation of models is required before general im-
plementation [30]. However, validation methods for an ap-
proach such as ours are not well developed. An RCE comprises
two principal components: (1) the dataset containing a set of
covariates and the outcome of interest; and (2) the mathematical
model applied to the data in the dataset. The application to a
population is specific to that population. In addition to the inter-
val censoring described above, screening data are also not pro-
portional. This makes problematic the use of widely accepted
statistics for assessing effectiveness of diagnostic tools based on
Kaplan–Meier methods. An approach to validation was devel-
oped, taking these constraints into account, comprising dataset
validation, model checking, internal validation (including data
splitting, bootstrapping, C-index) and estimation of sensitivities/
specificities at specified intervals, all recognised internal valida-
tion methods [30]. An implementation phase will include model
updating (temporal validation and model tuning) and the oppor-
tunity for comparative cross population (external) validation to
correct for potential overperformance [31].
We believe that the Liverpool RCE is feasible, reliable, safe
and acceptable to patients. Implementation of our RCE into
routine clinical practice would offer potentially significant
transfer of resources into targeting high-risk and hard-to-reach
groups and improved cost-effectiveness. Based on the internal
validations we have performed, it shows sufficient performance
for a local introduction. However, wider implementation will
require an external validation process and testing of safety and
acceptability in an RCT setting [31]. Investment in IT systems
will be required for implementation in large-scale health sys-
tems, such as the NHS, and to support further validation.
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